Pharma Stocks
-
Gland Pharma: What Should You Do?
Gland pharma is primarily a generic injectables manufacturing and CDMO (Contract Development and Manufacturing Outsourcing) company. Its growth will be…
Read More » -
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) After Rival ATTR-CM Setback And New Partnerships
Recently, Alnylam Pharmaceuticals gained attention after a rival ATTR-CM therapy from AstraZeneca and Ionis failed in a late-stage trial, while…
Read More » -
FDA’s PADCEV Keytruda Approval for All MIBC Patients Might Change The Case For Investing In Astellas Pharma (TSE:4503)
Pfizer and Astellas Pharma recently announced that the U.S. FDA approved PADCEV (enfortumab vedotin-ejfv) plus Keytruda as both neoadjuvant and…
Read More » -
Should You Buy Eli Lilly Stock? Here’s My Honest Take.
Eli Lilly(NYSE: LLY) is in a league of its own. It’s the largest healthcare company in the world by market…
Read More » -
ACADIA Pharmaceuticals (ACAD) Names A New Chief People Officer, Is It Still Below Fair Value?
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors…
Read More » -
Is This Biotech Stock a Buy Near Its 52-Week High?
Key Points Vertex Pharmaceuticals is making clinical and regulatory progress with some promising candidates. The company’s most important business is…
Read More » -
Is ACADIA Pharmaceuticals (ACAD) Still Undervalued After The Daybue Win?
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors…
Read More » -
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?
Vertex Pharmaceuticals (VRTX 0.45%) is a biotech company that has steadily delivered growth to investors, thanks to its dominance in…
Read More » -
Russell 1000 Defensive Inclusion Might Change The Case For Investing In Royalty Pharma (RPRX)
Royalty Pharma plc (NasdaqGS:RPRX) was added to both the Russell 1000 Value-Defensive Index and the Russell 1000 Defensive Index on…
Read More » -
ANI Pharmaceuticals CFO Sells $240,000 in Stock After a 42% Cortrophin Surge
Stephen Carey, SVP & CFO of ANI Pharmaceuticals (ANIP 1.17%), reported the sale of 2,850 shares of common stock in…
Read More »
